FY2025 SEC EDGAR DEF 14A #1 of 168 in industry

Keenova Therapeutics plc CEO pay ratio

The CEO earned $47.4M in FY2025 against median worker pay of $108,968 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
L2
Filing date
2026-04-27
Industry
Chemicals & Pharmaceuticals
Industry rank
#1/168

Data updated August 2026

Subscribe to Keenova Therapeutics plc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
435:1
Extreme (Scale: 0–1000:1)
CEO pay
$47.4M
Median worker
$108,968

Answer first

Keenova Therapeutics plc's FY2025 CEO total of $47.4M ranks #28 of 1,423 complete filings; its 435:1 pay ratio ranks #121. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $108,968. Industry placement uses the FY2025 SIC-28 peer cohort (# 1 of 168, 100th percentile - top 1% of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#28
$47.4M of 1,423 FY2025
Ratio rank
#121
435:1 of 1,423
Industry pct
100th
top 1% of industry peers by pay ratio

How Keenova Therapeutics plc ranks nationally

Keenova Therapeutics plc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$47,401,080 Top 2% higher than 98% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). Below this entry. $15,000,000–$17,500,000: 88 companies (6%). Below this entry. $17,500,000–$20,000,000: 54 companies (4%). Below this entry. $20,000,000–$22,500,000: 24 companies (2%). Below this entry. $22,500,000–$25,000,000: 34 companies (2%). Below this entry. $25,000,000–$27,500,000: 24 companies (2%). Below this entry. $27,500,000–$30,000,000: 16 companies (1%). Below this entry. $30,000,000–$32,500,000: 10 companies (1%). Below this entry. $32,500,000–$35,000,000: 7 companies (0%). Below this entry. $35,000,000–$37,500,000: 9 companies (1%). Below this entry. $37,500,000–$40,000,000: 6 companies (0%). Below this entry. $40,000,000–$42,500,000: 1 companies (0%). Below this entry. $42,500,000–$45,000,000: 1 companies (0%). Below this entry. $45,000,000–$47,500,000: 6 companies (0%). This entry sits in this band. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Keenova Therapeutics plc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($47.4M) against pay ratio (435:1) for Keenova Therapeutics plc (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both5924457.816787382.627650307.538513232.449376157.322.3:1130.4:1238.5:1346.6:1454.6:1CEO total payPay ratio (CEO : median worker)Keenova Therapeutics plc, CEO total pay: 47401080 · Pay ratio (CEO : median worker): 435:1Keenova Therapeutics plcLinde PLC, CEO total pay: 21777870 · Pay ratio (CEO : median worker): 428:1Linde PLCBausch Health Companies Inc., CEO total pay: 16877326 · Pay ratio (CEO : median worker): 401:1Bausch Health Companies Inc.Ppg Industries Inc, CEO total pay: 16555264 · Pay ratio (CEO : median worker): 352:1Ppg Industries IncViatris Inc, CEO total pay: 15280383 · Pay ratio (CEO : median worker): 327:1Viatris IncELI LILLY & Co, CEO total pay: 36698337 · Pay ratio (CEO : median worker): 293:1ELI LILLY & Co
Keenova Therapeutics plc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Keenova Therapeutics plc's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Keenova Therapeutics plc

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
435:1
FY2025
vs prior FY
+201:1
from FY2024 234:1
CEO $ YoY
+74%
$47.4M latest
Filings shown
3
FY2022–2025
Keenova Therapeutics plc CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $8.3M - $104,032 80:1 -
2024 $27.3M +228% $116,620 234:1 +154:1
2025 $47.4M +74% $108,968 435:1 +201:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1567892, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
435:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$47.4M
Companies in Industry
168
vs. Industry Median
Above
#1 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Keenova Therapeutics plc: HIGH · OUTLIER pay ratio

Keenova Therapeutics plc's FY2025 ratio 435:1 ranks #1 of 168 Chemicals & Pharmaceuticals filers (100th percentile). the CEO earned 435× the median employee ($108,968) in FY2025.

Median employee $108,968 (HIGH-MED); HIGH · OUTLIER stamps put about 435 median-wage years per CEO year.

CEO Total Pay

$47.4M

FY2025 Summary Compensation, well above median

Pay Ratio

435:1

Outlier, top decile

Keenova Therapeutics plc in the higher Chemicals & Pharmaceuticals third

Keenova Therapeutics plc's FY2025 ratio 435:1 ranks #1 of 168 Chemicals & Pharmaceuticals filers (100th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Keenova Therapeutics plc's $47.4M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #28 and ratio rank #121 split - treat 435:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$47.4M
Median Employee Pay
$108,968
Pay Ratio
435:1
Filing Date
2026-04-27

Company Info

CIK
1567892
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
L2
View SEC filings →
SEC EDGAR DEF 14A for CIK 1567892, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Keenova Therapeutics plc's FY2025 ratio 435:1 ranks #1 of 168 Chemicals & Pharmaceuticals filers (100th percentile).

Read with Keenova Therapeutics plc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps HIGH · OUTLIER · HIGH-MED.

Match Group, Inc. · OUTLIER

ABS(ceo_total_comp) peer at $47.2M (Δ $241K lighter vs Keenova Therapeutics plc); STEEP · ELITE-MED vs this page's HIGH · OUTLIER · HIGH-MED.
DXC Technology Co · OUTLIER

ABS(ceo_total_comp) peer at $47.8M (Δ $378K heavier vs Keenova Therapeutics plc); MEGA · LOW-MED vs this page's HIGH · OUTLIER · HIGH-MED.
Core Natural Resources, Inc. · OUTLIER

ABS(ceo_total_comp) peer at $46.4M (Δ $1.0M lighter vs Keenova Therapeutics plc); HIGH · ELITE-MED vs this page's HIGH · OUTLIER · HIGH-MED.
Somnigroup International Inc. · OUTLIER

ABS(ceo_total_comp) peer at $45.9M (Δ $1.5M lighter vs Keenova Therapeutics plc); EXTREME · PAR-MED vs this page's HIGH · OUTLIER · HIGH-MED.
Linde PLC (SIC 28 pole)

Linde PLC stamps HIGH · PEAK nearest in-SIC by ABS(pay_ratio) to Keenova Therapeutics plc's HIGH filing.
National dual ranks · #28/#121

Keenova Therapeutics plc's FY2025 package sits #28 by CEO dollars and #121 by ratio under OUTLIER · HIGH.
Comp structure · OUTLIER

Keenova Therapeutics plc's OUTLIER CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for Keenova Therapeutics plc (CIK 1567892), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.